Vanda Pharmaceuticals Reports Q2 2026 Results

What Happened
Vanda Pharmaceuticals Inc. filed a Form 8-K on August 5, 2026 to announce a press release and an earnings conference call reporting its results of operations and financial condition for the quarter ended June 30, 2026. The press release is furnished as Exhibit 99.1 to the filing. The company noted that statements made during the call may include forward-looking statements about commercial products, development programs, timelines and commercial potential.

Key Details

• Filing date: August 5, 2026.
• Reporting period: quarter ended June 30, 2026.
• Press release furnished as Exhibit 99.1 and an earnings call was held to discuss quarterly results and financial condition.
• The company included standard forward-looking statement language and said it does not undertake any obligation to update those statements except as required by law.

Why It Matters
This 8-K signals that Vanda has publicly reported its quarterly results; investors should review the press release and listen to the earnings call for specific revenue, profit and guidance figures. The forward-looking statements warning means any discussion of future performance, product approvals or timelines is subject to risks and uncertainties—investors should compare these comments with Vanda’s recent 10-K/10-Q risk disclosures before making decisions.